comparemela.com
Home
Live Updates
PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology : comparemela.com
PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology
– Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically – Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma...
Related Keywords
Australia ,
Melbourne ,
Victoria ,
Canada ,
Toronto ,
Ontario ,
San Francisco ,
California ,
United States ,
Australian ,
Like Ahmed ,
Russell Tait ,
Michael Coote ,
Polyactiva Pty Ltd ,
Prezia Technology ,
Drug Delivery Technology ,
University Of Utah ,
Horizons Forum ,
University Of Toronto ,
Prezia Sustained Drug Delivery Technology ,
Prism Eye Institute In Ontario ,
Secondary Efficacy Endpoints Met ,
Significant Reduction ,
Intra Ocular Pressure ,
Ocular Implant ,
Primary Open Angle Glaucoma ,
Chief Executive Officer ,
Annual Glaucoma ,
Associate Professor Michael Coote ,
Melbourne Eye Specialists ,
Prism Eye Institute ,
Assistant Professor ,
Clinical Professor ,
Sustained Drug Delivery Technology ,
comparemela.com © 2020. All Rights Reserved.